Antiphospholipid syndrome: Reversal of antiphosphatidylserine/prothrombin-induced activated protein C resistance

Background: Anti-phosphatidylserine/prothrombin (aPS/PT) antibodies are the major contributor to activated Protein C resistance (APC-R) in tetra-positive thrombotic high-risk patients with Antiphospholipid Syndrome (APS). Objectives: To evaluate the role of phospholipids (PL) on aPS/PT mediated APC-R. Patients/methods: Total IgG were purified from plasma of 6 tetra-positive patients and IgG aPS/PT were affinitypurified from 3 of these patients. Purified material was spiked into Normal Pooled Plasma (NPP) and tested for APC-R in thrombin generation assay and in Factor Va inactivation assay using increasing amounts of phospholipids. Results and conclusions: Total IgG showed APC-R at low PL concentration (1.5 mu g/mL) that disappeared at increasing PL concentrations (5.8, 11.6 and 46.6 mu g/mL). In the same way, affinity purified aPS/PT showed a robust (59 %, 52 %, 36 %) APC-R in patients #4, #5 and #6, respectively at low PL concentration (1.5 mu g/mL) that was completely reversed at higher concentration (11.6 mu g/mL). The inactivation of FVa by activated Protein C (aPC) was impaired in the presence of aPS/PT at low aPL concentration and reversed by increasing amounts of PL. These data point out the relevance of PL in reversing APC-R in this 'in vitro' system. The mechanism for reversal might be explained by loss of PL availability for aPC. These results may give some insight into the pathogenesis of thrombosis or suggestions for alternative treatments.